COMP <GO>
OPK vs SNDX // OPTIONS IMPLIED MOVE & PUT/CALL SKEW
OPKO Health Inc. (NASDAQ) VS. Syndax Pharmaceuticals Inc. (NASDAQ) • 15-METRIC TALLY: OPK 4
— SNDX 2
■ METRIC PARITY
LAST: $1.66 (+2.47%) • MKT CAP: $1.24B
options-implied-move
—
LAST: $14.15 (-1.19%) • MKT CAP: $1.26B
options-implied-move
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (OPK VS. SNDX)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | OPK | SNDX | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 33.90% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -10.20% | -35.00% | +24.80 | OPK | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -14.41% | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | -19.30% | -60.00% | +40.70 | OPK | /operating-margins <GO> |
| Net Profit Margin | -60.00% | -60.00% | 0.00 | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | -14.90% | 180.00% | -194.90 | SNDX | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.20 | 0.20 | 0.00 | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 4/9 | 3/9 | +1.00 | OPK | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew ACTIVE | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 58.9 | 35.8 | +23.10 | OPK | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.24B | $1.26B | -$24.6M | SNDX | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | OPK REV | SNDX REV | OPK GROSS % | SNDX GROSS % | OPK FCF | SNDX FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $606.9M | $172.4M | 33.9% | — | -$178.5M | -$323.2M |
| FY 2024 | $713.1M | $23.7M | 30.6% | — | -$183.5M | -$274.9M |
| FY 2023 | $863.5M | $0 | — | — | -$28.2M | -$160.6M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
OPK // BETA —
SNDX // BETA —